Thursday, 15 October 2026European Markets

CASINO GUICHARD Stock Slides By 29% In The Last 21 Sessions

Loading stream...

(vianews) - shares of casino guichard (cac 40: co.pa) slid by a staggering 29.19% in 21 sessions from €8.6 to €6.09 at 14:54 est on friday, following the last session's upward trend. cac 40 is jumping 0.12% to €7,324.75, following the last session's upward trend.

casino guichard's last close was €6.09, 68.4% below its 52-week high of €19.27.

about casino guichard

casino, guichard-perrachon s.a. operates as a food retailer in france, latin america, and internationally. the company operates hypermarkets, supermarkets, shopping malls, and e-commerce sites, as well as convenience, discount, and cash and carry stores. it also involved in banking, digital marketing, service station, franchise, real estate asset management, property development and trading, rental, banking, and energy-related activities. it operates through stores. the company was founded in 1898 and is based in saint-étienne, france.

earnings per share

as for profitability, casino guichard has a trailing twelve months eps of €-8.54.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.53%.

volume

today's last reported volume for casino guichard is 255769 which is 35.29% below its average volume of 395265.

moving average

casino guichard's value is way under its 50-day moving average of €9.64 and way under its 200-day moving average of €10.82.

more news about casino guichard (co.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com